Continued enrollment in expanded ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors ADXS-503 Phase 1/2 trial data presented at SITC demonstrated disease control rate of 67% and overall response rate of 17% in first six evaluable

PRINCETON, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Precision for Medicine, a specialized services company supporting next generation approaches to

Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors SITC presentation from ongoing ADXS-503 Phase 1/2 clinical trial demonstrated disease control rate of 67% and overall response rate of 17% in first six

Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program PRINCETON, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) --  Advaxis, Inc.  (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today

PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it received a positive determination from the Nasdaq Stock Market granting

PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) --  Advaxis, Inc. (Nasdaq: ADXS)  (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an underwritten public offering of 26,666,666 shares

PRINCETON, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) --  Advaxis, Inc. (Nasdaq: ADXS)  (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of (i) 26,666,666

PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) --  Advaxis, Inc. (Nasdaq: ADXS)  (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it intends to offer and sell shares of its common stock and

Disease control rate of 67%  and overall response rate of 17%  in first six evaluable patients   with immediate prior progression  on KEYTRUDA ® Biomarker data confirms on-mechanism activation of innate and adaptive immune responses to ADXS-503 ADXS-503 appeared safe and well tolerated as a

Disease control rate of 67% in first six evaluable patients  who had progressed on KEYTRUDA Approximate 50% improvement  in  disease control rate  versus the rate s  reported  in  other checkpoint rechallenge studies Durable, sustained  tumor control  of  over  43 and   33 weeks observed in  first